Apoptosis control by death and decoy receptors

Current Opinion in Cell Biology

Volumn 11, Issue 2, 1999, Pages 255-260

  Ashkenazi, Avi ^a   Dixit, Vishva M ^a  

^a GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE; CELL RECEPTOR; FAS ANTIGEN; FAS LIGAND; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR;

APOPTOSIS; KNOCKOUT MOUSE; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

EID: 0032910169     PISSN: 09550674     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0955-0674(99)80034-9     Document Type: Article

References (66)

1. Steller H. Mechanisms and genes of cellular suicide. Science. 267:1995;1445-1449.
2. Jacobson M.D., Weil M., Raff M.C. Programmed cell death in animal development. Cell. 88:1997;347-354.
3. Nagata S. Apoptosis by death factor. Cell. 88:1997;355-365.
4. Ashkenazi A., Dixit V.M. Death receptors: signaling and modulation. Science. 281:1998;1305-1308. A detailed review of signaling by death receptors; includes nonapoptotic functions.
5. Gruss H.J., Dower S.K. Tumor necrosis factor ligand superfamily: involvement in the pathology of malignant lymphomas. Blood. 85:1995;3378-3404.
6. Pitti R.M., Marsters S.A., Ruppert S., Donahue C.J., Moore A., Ashkenazi A. Induction of apoptosis by Apo-2 Ligand, a new member of the tumor necrosis factor receptor family. J Biol Chem. 271:1996;12687-12690.
7. Wiley S.R., Schooley K., Smolak P.J., Din W.S., Huang C.P., Nicholl J.K., Sutherland G.R., Smith T.D., Rauch C., Smith C.A.et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity. 3:1995;673-682.
8. Screaton G.R., Mongkolsapaya J., Xu X.N., Cowper A.E., McMichael A.J., Bell J.I. TRICK2, a new alternatively spliced receptor that transduces the cytotoxic signal from TRAIL. Curr Biol. 7:1997;693-696.
9. Martinez-Lorenzo M.J., Alava M.A., Gamen S., Kim J.K., Chuntharapai A., Pineiro A., Naval J., Anel A. Involvement of Apo2 ligand/TRAIL in activation-induced death of Jurkat and human peripheral blood T cells. Eur J Immunol. 28:1998;2714-2725.
10. Jeramias I., Herr I., Boehler T., Debatin K.M. TRAIL/Apo-2-ligand-induced apoptosis in human T cells. Eur J Immunol. 28:1998;143-152.
11. Marsters S., Pitti R., Donahue C., Ruppert S., Bauer K., Ashkenazi A. Activation of apoptosis by Apo-2 ligand is independent of FADD but blocked by CrmA. Curr Biol. 6:1996;750-752.
12. Snell V., Clodi K., Zhao S., Goodwin R., Thomas E.K., Morris S.W., Kadin M.E., Cabanillas F., Andreeff M., Younes A. Activity of TNF-related apoptosis-inducing ligand (TRAIL) in haematological malignancies. Br J Haematol. 99:1997;618-624.
13. Thomas W.D., Hersey P. TNF-related apoptosis-inducing ligand (TRAIL) induces apoptosis in Fas ligand-resistant melanoma cells and mediates CD4 T cell killing of target cells. J Immunol. 161:1998;2195-2200.
14. Marsters S.A., Sheridan J.P., Pitti R.M., Brush J., Goddard A., Ashkenazi A. Identification of a ligand for the death-domain-containing receptor Apo3. Curr Biol. 8:1998;525-528.
15. Chicheportiche Y., Bourdon P.R., Xu H., Hsu Y., Scott H., Hession C., Garcia I., Browning J.L. TWEAK, a new secreted ligand in the TNF family that weakly induces apoptosis. J Biol Chem. 272:1997;32401-32410.
16. Smith C.A., Farrah T., Goodwin R.G. The TNF receptor superfamily of cellular and viral proteins: activation, costimulation, and death. Cell. 76:1994;959-962.
17. Tartaglia L.A., Ayers T.M., Wong G.H.W., Goeddel D.V. A novel domain within the 55 kd TNF receptor signals cell death. Cell. 74:1993;845-853.
18. Itoh N., Nagata S. A novel protein domain required for apoptosis: mutational analysis of human Fas antigen. J Biol Chem. 268:1993;10932-10937.
19. Chinnaiyan A.M., O'Rourke K., Yu G.L., Lyons R.H., Garg M., Duan D.R., Xing L., Gentz R., Ni J., Dixit V.M. Signal transduction by DR3, a death domain-containing receptor related to TNFR-1 and CD95. Science. 274:1996;990-992.
20. Marsters S., Sheridan J., Donahue C., Pitti R., Gray C., Goddard A., Bauer K.D., Ashkenazi A. Apo3, a new member of the tumor necrosis factor receptor family, contains a death domain and activates apoptosis and NF-κB. Curr Biol. 6:1996;1669-1676.
21. Kitson J., Raven T., Jiang Y.P., Goeddel D.V., Giles K.M., Pun K.T., Grinham C.J., Brown R., Farrow S.N. A death-domain-containing receptor that mediates apoptosis. Nature. 384:1996;372-375.
22. Bodmer J.L., Burns K., Schneider P., Hofmann K., Steiner V., Thome M., Bornand T., Hahne M., Schroter M., Becker K.et al. TRAMP, a novel apoptosis-mediating receptor with sequence homology to tumor necrosis receptor 1 and Fas (Apo-1/CD95). Immunity. 6:1997;79-88.
23. Screaton G., Xu X., Olsen A., Cowper A., Tan R., McMichael A., Bell J.I. LARD: a new lymphoid-specific death domain containing receptor regulated by alternative pre-mRNA splicing. Proc Natl Acad Sci USA. 94:1997;4615-4619.
24. Pan G., O'Rourke K., Chinnaiyan A.M., Gentz R., Ebner R., Ni J., Dixit V.M. The receptor for the cytotoxic ligand TRAIL. Science. 276:1997;111-113.
25. Pan G., Dixit V.M. An antagonist decoy receptor and a new death domain-containing receptor for TRAIL. Science. 277:1997;815-818.
26. Sheridan J.P., Marsters S.A., Pitti R.M., Gurney A., Skubatch M., Baldwin D., Ramakrishnan L., Gray C.L., Baker K., Wood W.I.et al. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science. 277:1997;818-821.
27. Walczak H., Degli-Esposti M.A., Johnson R.S., Smolak P.J., Waugh J.Y., Boiani N., Timour M.S., Gerhart M.J., Schooley K.A., Smith C.A.et al. TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL. EMBO J. 16:1997;5386-5397.
28. Wu G.S., Burns T.F., McDonald E.R., Jiang W., Meng R., Krantz I.D., Kao G., Gan D.D., Zhou J.Y., Muschel R.et al. KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene. Nat Genet. 17:1997;141-143.
29. McFarlane M., Ahmad M., Srinivasula S.M., Fernandes-Alnemri T., Cohen G.M., Alnemri E.S. Identification and molecular cloning of two novel receptors for the cytotoxic ligand TRAIL. J Biol Chem. 272:1997;25417-25420.
30. Schneider P., Bodmer J.L., Thome M., Hofmann K., Hohller N., Tschopp J. Characterization of two receptors for TRAIL. FEBS Lett. 416:1997;329-334.
31. Degli-Esposti M., Smolak P.J., Walczak H., Waugh J., Huang C.P., Dubose R.F., Goodwin R.G., Smith C.A. Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family. J Exp Med. 186:1997;1165-1170.
32. Mongkolsapaya J., Cowper A., Xu X.N., Morris G., McMichael A., Bell J.I., Screaton G.R. Lymphocyte inhibitor of TRAIL: a new receptor protecting lymphocytes from the death ligand TRAIL. J Immunol. 160:1998;3-6.
33. Marsters S.A., Sheridan J.P., Pitti R.M., Huang A., Skubatch M., Baldwin D., Yuan J., Gurney A., Goddard A.D., Godowski P., Ashkenazi A. A novel receptor for Apo2L/TRAIL contains a truncated death domain. Curr Biol. 7:1997;1003-1006.
34. Pan G., Ni J., Yu G.L., Wei Y.F., Dixit V.M. TRUNDD, a new member of the TRAIL receptor family that antagonizes TRAIL signaling. FEBS Lett. 424:1998;41-45.
35. Degli-Esposti M.A., Dougall W.C., Smolak P.J., Waugh J.Y., Smith C.A., Goodwin R.G. The novel receptor TRAIL-R4 induces NF-κB and protects aginst TRAIL-mediated apoptosis, yet retains an incomplete death domain. Immunity. 7:1997;813-820.
36. Simonet W.S., Lacey D.L., Dunstan C.R., Kelley M., Chang M.S., Luthy R., Nguyen H.Q., Wooden S., Bennett L., Boone T.et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell. 89:1997;309-319.
37. Pitti, R., Marsters, S.A., Lawrence, D.A., Roy, M., Kischkel, F.C., Dowd, P., Huang, A., Donahue, C.J., Sherwood, S.W., Baldwin, D.T. et al.: Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer. 1998, 396:699-703. A secreted decoy receptor that blocks apoptosis-induction by FasL was discovered on the basis of homology to the TNFR family. The gene encoding the decoy is amplified in about half of 35 primary lung and colon cancers studied, which suggests that this decoy receptor may well be involved in immune-evasion by tumors.
38. Golstein P. Cell death: TRAIL and its receptors. Curr Biol. 7:1997;750-753.
39. Emery J.G., McDonell P., Burke M.C., Deen K.C., Lyn S., Silverman C., Dul E., Appelbaum E.R., Eichman C., DiPrinzio R.et al. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem. 273:1998;14363-14367.
40. Pan G., Bauer J.H., Haridas V., Wang S., Liu D., Yu G., Vincenz C., Aggarwal B.B., Ni J., Dixit V.M. Identification and functional characterization of DR6, a novel death domain-containing TNF receptor. FEBS Lett. 431:1998;351-356. DR6 was discovered on the basis of homology to the TNFR family. DR6 is unique in that it appears to bind the adaptor TRADD but not FADD. This is in contrast to Fas, which binds FADD but not TRADD, and to TNFR1, which binds FADD immediately through TRADD.
41. Thornberry N.A., Lazebnik Y. Caspases: enemies within. Science. 281:1998;1312-1316.
42. Enari M., Sakahira H., Yokoyama H., Okawa K., Iwamatsu A., Nagata S. A caspase-activated DNase that degrades DNA during apoptosis, and its inhibitor ICAD. Nature. 391:1998;43-50.
43. Sakahira H., Enari M., Nagata S. Cleavage of CAD inhibitor in CAD activation and DNA degradation during apoptosis. Nature. 391:1998;96-99.
44. Liu X., Zou H., Slaughter C., Wang X. DFF, a heterodimeric protein that functions downstream of caspase-3 to trigger DNA fragmentation during apoptosis. Cell. 89:1997;175-184.
45. Kelliher M., Grimm S., Ishida Y., Kuo F., Stanger B.Z., Leder P. The death domain kinase RIP mediates the TNF-induced NF-κB signal. Immunity. 8:1998;297-303.
46. Yeh W.C., Shahinian A., Speiser D., Kraunus J., Billia F., Wakeham A., de la Pompa J.L., Ferrick D., Hum B., Iscove N.et al. Early lethality, functional NF-κB activation, and increased sensitivity to TNF-induced cell death in TRAF2-deficient mice. Immunity. 7:1997;715-725.
47. Lee S.Y., Reichlin A., Santana A., Sokol K.A., Nussenzweig M.C., Choi W. TRAF2 is essential for JNK but not NF-κB activation and regulates lymphocyte proliferation and survival. Immunity. 7:1997;703-713.
48. Malinin N.L., Boldin M.P., Kovalenko A.V., Wallach D. MAP3K-related kinase involved in NF-κB induction by TNF, CD95 and IL-1. Nature. 385:1997;540-544.
49. Scheidereit C. Docking IκB kinases. Nature. 395:1998;225-226.
50. Nishitoh H., Saitoh M., Mochida Y., Takeda K., Nakano H., Rothe M., Miyazono K., Ichijo H. ASK1 is essential for JNK/SAPK activation by TRAF2. Mol Cell. 2:1998;389-395.
51. Yeh W.C., Pompa J.L., McCurrach M.E., Shu H.B., Elia A.J., Shahinian A., Ng M., Wakeham A., Khoo W., Mitchell K.et al. FADD: essential for embryo development and signaling from some, but not all, inducers of apoptosis. Science. 279:1998;1954-1958. By knocking out the FADD gene in mice, the authors establish that FADD is essential for apoptosis induction by Fas, TNFR1 and DR3. There are conflicting reports on the ability of the dominant-negative FADD mutants to block apoptosis-induction by Apo2L. This study shows that transfection of FADD-deficient cells with Apo2L receptor DR4 induced apoptosis; thus, FADD is not required for apoptosis signaling through DR4.
52. Newton K., Harris A.W., Bath M.L., Smith K.G.C., Strasser A. A dominant interfering mutant of FADD/MORT1 enhances deletion of autoreactive thymocytes and inhibits proliferation of mature T lymphocytes. EMBO J. 17:1998;706-718. Transgenic mice expressing a dominant-negative FADD mutation in T cells show a defect in Fas-induced apoptosis as expected. Suprisingly, these mice also show a defect in the proliferative response to their T cells to antigenic stimulation, which implicates FADD in regulating not only death but also proliferation of cells.
53. Zornig M., Hueber A.O., Evan G. p53-dependent impairment of T-cell proliferation in FADD dominant-negative transgenic mice. Curr Biol. 8:1998;467-470. This study provides evidence that the dominant-negative FADD impairs activation-induced proliferation of thyrmocytes through a mechanism that appears to involve the p53 tumor suppressor gene.
54. Zhang J., Cado D., Chen A., Kabra N.H., Winoto A. Fas-mediated apoptosis and activation-induced T-cell proliferation are defective in mice lacking FADD/Mort1. Nature. 392:1998;296-300. By deleting the FADD gene in mice, the authors demonstrate that FADD is essential for apoptosis-induction by Fas and TNFR1. Although Fas or TNFR1 knockouts in the mouse are not lethal FADD gene knockout is, which suggests that FADD has additional roles besides signaling downstream of these latter receptors. Rescue of the mice by the breeding with RAG-1 knockout mice revealed a defect in T cell proliferation in response to antigenic stimulation, which is consistent with the results from transgenic mice expressing dominant-negative FADD.
55. Varfolomeev E.E., Schuchmann M., Luria V., Chiannilkulchai N., Beckmann J.S., Mett I.L., Rebrikov D., Brodianski V.M., Kemper O.C., Kollet O.et al. Targeted disruption of the mouse Caspase-8 gene ablates cell death induction by the TNF receptors, Fas/Apo1, and DR3 and is lethal prenatally. Immunity. 9:1998;267-276. Biochemmical studies have implicated the capase-8 in death signaling by several death receptors. By deleting the mouse capase-8 gene, the authors show that capase-8 plays an essential role in apoptosis-induction by Fas, TNFR1 and DR3.
56. Juo P., Kuo C.J., Yuan J., Blenis J. Essential requirement for caspase 8/FLICE in the initiation of the Fas-induced apoptotic cascade. Curr Biol. 8:1998;1001-1008. The authors isolated a mutant human T cell line that is deficient in capase-8. Using this cell line, they show that in the absence of capase-8, Fas-induced apoptosis is abolished completely; suprisingly TNF-induced apoptosis is only partially prevented.
57. Woo M., Hakem R., Soengas M.S., Duncan G.S., Shahinian A., Kagi D., Hakem A., McCurrach M., Khoo W., Kaufman S.A.et al. Essential contribution of caspase-3/CPP32 to apoptosis and its associated nuclear changes. Genes Dev. 12:1998;806-819. Results with caspase-3-deficient cells implicate this capase in the nuclear changes that occur during apoptosis induced by Fas-ligation and other apototic stimuli.
58. Green D.R., Reed J.C. Mitochondria and apoptosis. Science. 281:1998;1309-1312.
59. Wang K., Ying X.M., Chao D.T., Milliman C.L., Korsmeyer S. BID: a novel BH3 domain-only death agonist. Genes Dev. 10:1996;2859-2869.
60. Luo X., Budihardjo I., Zou H., Slaughter C., Wang X. Bid, a Bcl2 interacting protein, mediates cytochrome C release from mitochondria in response to activation of cell surface death receptors. Cell. 94:1998;481-490.
61. Li H., Zhu H., Xu C.J., Yuan J. Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell. 94:1998;491-501.
62. Cecconi F., Alvarez-Bolado G., Meyer B.I., Roth K.A., Gruss P. Apaf1 (CED-4 homolog) regulates programmed cell death in mammalian development. Cell. 94:1998;727-737.
63. Yoshida H., Kong Y.Y., Yoshida R., Elia A.J., Hakem A., Hakem R., Penninger J.M., Mak T.W. Apaf1 is required for mitochondrial pathways of apoptosis and brain development. Cell. 94:1998;739-750.
64. Kuida K., Haydar T.F., Kuan C.Y., Gu Y., Taya C., Karasuyama H., Su M.S., Rakic P., Flavell R.A. Reduced apoptosis and cytochrome c-mediated caspase activation in mice lacking caspase 9. Cell. 94:1998;325-337.
65. Hakem R., Hakem A., Duncan G.S., Henderson J.T., Soengas M.S., Elia A., de la Pompa J.L., Kagi D., Khoo W.et al. Differential requirement for caspase 9 in apoptotic pathways in vivo. Cell. 94:1998;339-352.
66. Stegh A.H., Schickling O., Ehret A., Scaffidi C., Peterhansel C., Hofmann T.G., Grummt I., Krammer P.H., Peter M.E. DEDD, a novel death effector domian-containing protein, targeted to the nucleus. EMBO J. 17:1998;5974-5986. DEDD was identified by virtue of its homology to the death effector domains of FADD and capase-8. Unlike other adaptor molecules, DEDD moves from the cytoplasm to the nucleus upon Fas-ligation; this, together with an ability to inhibit transcription in a reconstituted system, suggests a possible molecular mechanism for shutting down gene expression in cells which are undergoing apoptotic death.